Literature DB >> 699283

Modified erythrocyte uroporphyrinogen I synthase assay, and its clinical interpretation.

M W Piepkorn, P Hamernyik, R F Labbé.   

Abstract

Assay of erythrocyte uroporphyrinogen I synthase is an accepted diagnostic test for acute intermittent porphyria, particularly in those individuals who are asymptomatic or in whom the disease is not biochemically manifested by excretion of excess porphyrin precursor. The assay described is based upon a coupled-enzyme procedure in which added delta-aminolevulinic acid and its dehydratase present in erythrocytes are used to generate porphobilinogen as substrate for uroporphyrinogen synthase. Zinc and dithiothreitol are added with preincubation to give maximum activity and reproducibility. These agents also prevent inhibition by lead. Healthy young women had a mean activity of 40 nmol of porphyrin formed per milliliter of erythrocytes per hour, men and activity of 38 nmol/ml/h. Preparation of control specimens is described. This assay gave within-day CVs ranging from 1.9 to 2.8%. Precautions in interpretation of results are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 699283

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Safety of vancomycin in acute porphyria.

Authors:  R Hift; U Sohnius; P N Meissner
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

2.  A modified spectrophotometric assay for porphobilinogen deaminase: its application in the detection of both carriers and patients with acute intermittent porphyria.

Authors:  J Vázquez-Prado; F J Sánchez-Anzaldo; G J Ruiz-Argüelles; E Marín-López; E Lobato-Mendizábal
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

3.  Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria.

Authors:  P Meissner; P Adams; R Kirsch
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

4.  Heme biosynthesis and porphyrin studies in chronic renal failure patients following kidney transplantation.

Authors:  M el-Far; M Sobh; M Ghoniem
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

5.  The effects of chronic carbamazepine treatment of haem biosynthesis in man and rat.

Authors:  G M McGuire; G J Macphee; G G Thompson; B K Park; M R Moore; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Detection of seven point mutations in the porphobilinogen deaminase gene in patients with acute intermittent porphyria, by direct sequencing of in vitro amplified cDNA.

Authors:  C S Mgone; W G Lanyon; M R Moore; J M Connor
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

7.  Plumboporphyria (ALAD deficiency) in a lead worker: a scenario for potential diagnostic confusion.

Authors:  J Dyer; D P Garrick; A Inglis; I F Pye
Journal:  Br J Ind Med       Date:  1993-12

8.  Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity.

Authors:  A L Herrick; K E McColl; M R Moore; M J Brodie; A R Adamson; A Goldberg
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

9.  Porphyrin metabolism in some malignant diseases.

Authors:  M M el-Sharabasy; A M el-Waseef; M M Hafez; S A Salim
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

10.  Pathogenesis and treatment of acute intermittent porphyria: discussion paper.

Authors:  A C Laiwah; A Goldberg; M R Moore
Journal:  J R Soc Med       Date:  1983-05       Impact factor: 18.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.